Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

Item

http://www.wikidata.org/entity/Q36924102

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

@en

type

Item

label

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

@en

prefLabel

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

@en

P1476

Liraglutide in Type 2 Diabetes Mellitus: Clinical Pharmacokinetics and Pharmacodynamics

@en

P2093

Anette K Olsen

http://www.w3.org/2001/XMLSchema#string

Anne Flint

http://www.w3.org/2001/XMLSchema#string

Lisbeth V Jacobsen

http://www.w3.org/2001/XMLSchema#string

Steen H Ingwersen

http://www.w3.org/2001/XMLSchema#string

P275

Creative Commons Attribution-NonCommercial

P2860

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide.

Postprandial lipoprotein metabolism and atherosclerosis.

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

Liraglutide's safety, tolerability, pharmacokinetics, and pharmacodynamics in pediatric type 2 diabetes: a randomized, double-blind, placebo-controlled trial.

Influence of hepatic impairment on pharmacokinetics of the human GLP-1 analogue, liraglutide.

How useful is paracetamol absorption as a marker of gastric emptying? A systematic literature study.

Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study.

Effect of hemodialysis on plasma glucose profile and plasma level of liraglutide in patients with type 2 diabetes mellitus and end-stage renal disease: a pilot study

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6).

P2888

s40262-015-0343-6

P304

657-672

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1007/S40262-015-0343-6

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P5008

ScienceSource

P577

2015-11-23T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2016-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

284563088

http://www.w3.org/2001/XMLSchema#string

P698

26597252

http://www.w3.org/2001/XMLSchema#string

P921

Chidenhi

type-2 diabetes

maturity-onset diabetes of the young

P932

4875959

http://www.w3.org/2001/XMLSchema#string